Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
ADMA Biologics Inc (ADMA) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ADMA Biologics Inc (ADMA) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for January 31st
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 31st:
ADMA Biologics, Inc. (ADMA - Free Report) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.
ADMA Biologics Inc Price and Consensus
ADMA Biologics Inc price-consensus-chart | ADMA Biologics Inc Quote
ADMA’s shares gained 52% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.
ADMA Biologics Inc Price
ADMA Biologics Inc price | ADMA Biologics Inc Quote
Ekso Bionics Holdings, Inc. (EKSO - Free Report) : This exoskeleton products company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.6% over the last 60 days.
Ekso Bionics Holdings, Inc. Price and Consensus
Ekso Bionics Holdings, Inc. price-consensus-chart | Ekso Bionics Holdings, Inc. Quote
Ekso Bionics’ shares gained 56.9% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.
Ekso Bionics Holdings, Inc. Price
Ekso Bionics Holdings, Inc. price | Ekso Bionics Holdings, Inc. Quote
InhibikaseTherapeutics, Inc. (IKT - Free Report) : This clinical-stage pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 16% over the last 60 days.
Inhibikase Therapeutics, Inc. Price and Consensus
Inhibikase Therapeutics, Inc. price-consensus-chart | Inhibikase Therapeutics, Inc. Quote
Inhibikase’s shares gained 270.6% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of B.
Inhibikase Therapeutics, Inc. Price
Inhibikase Therapeutics, Inc. price | Inhibikase Therapeutics, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.